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Sarcopenia is defined as skeletal muscle attenuation and has an association with metabolic syndrome. 
Metabolic syndrome, which includes obesity, is one of known predictive factors for gastroesophageal 
reflux disease (GERD). This study aimed to elucidate the association between sarcopenia and GERD. 
We retrospectively reviewed electronic medical records of 8,218 patients who were performed an 
upper gastrointestinal endoscopy at check-up center of the Gangnam Severance Hospital. GERD was 
diagnosed by endoscopic findings. Erosive reflux disease (ERD) included Barrett's esophagus and 
reflux esophagitis, with the exception of minimal change esophagitis. Sarcopenia was defined by 
appendicular skeletal muscle (skeletal muscle in the upper and lower limbs). Sarcopenic obesity was 
defined as the presence of both sarcopenia and obesity. Associations between sarcopenia and GERD, as 
well as between sarcopenic obesity and ERD, were analyzed. A total of 3,414 patients were diagnosed 
with GERD, and 574 (16.8%) had sarcopenia. Sarcopenia was independent predictive factor for GERD 
(odds ratio [OR] = 1.170, 95% confidence interval [CI]: 1.016–1.346, P = 0.029). In addition, male sex, 
smoking, alcohol, and diet, including sweets and fatty food, had a significant association with GERD. 
A total of 1,423 (17.3%) of 8,218 patients were diagnosed with ERD, and 302 (21.2%) had sarcopenia. 
Male sex, smoking, and fatty food consumption had a significant association with ERD. Moreover, 
sarcopenia (OR = 1.215, 95% CI: 1.019–1.449, P = 0.030), obesity (OR = 1.343, 95% CI: 1.163–1.552, 
P < 0.001), and sarcopenic obesity (OR = 1.406, 95% CI: 1.195–1.654, P < 0.001) were independent 
predictive factors for ERD. Sarcopenia is associated with GERD, and sarcopenic obesity may be 
predictive factor for ERD.
Sarcopenia is progressive skeletal muscle attenuation that occurs as a consequence of the aging process. 
Baumgartner et al. first defined sarcopenia by appendicular skeletal muscle mass (skeletal muscle mass in the 
upper and lower limbs, ASM, kg)/height2 (m2) in 19981. Although there have been several different suggestive 
definitions of sarcopenia2–5, consensus definition for clinical research and practice is scarce3,6. The decline in 
muscle mass that begins around the fourth decade of life is approximately 25–30% during lifetimes7,8. With an 
increase in the world's advanced age population, the prevalence of sarcopenia has been increasing but has a wide 
variation according to the definition, method of measurement for muscle mass, age, race, and sex9,10. Sarcopenia 
is considered as a major health concern, because it is associated with physical disability, low quality of life, and 
mortality3,11. Previous studies have shown that sarcopenia has an association with metabolic syndrome. Since 
skeletal muscle is the main tissue for the insulin-dependent glucose uptake, sarcopenia is associated with the 
systemic insulin resistance that is a component of metabolic syndrome12,13. One study reported that sarcopenic 
obesity, which is the presence of both sarco penia and obesity that are associated with metabolic syndrome, has a 
greater impact on metabolic risk and health outcome6.
Gastroesophageal reflux disease (GERD) is a more common disease in Western populations than in Asian 
populations. A GERD prevalence of approximately 10–20% was identified in Western populations and was less 
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than 5% in Asian populations14. However, in Asia, the prevalence of GERD has been increasing dramatically 
over recent decades because of Westernized diets, extended life expectancy, and increased eradication rate of 
Helicobacter pylori15. Previous studies reported that metabolic syndrome and insulin resistance are one of the risk 
factors for GERD. One study reported that an increased triglyceride (TG) level, which is associated with meta-
bolic syndrome, is an independent risk factor for GERD16. Interleukin (IL)−6 is a cytokine that stimulates hepatic 
TG secretion, has a key role in insulin resistance17,18, and is increased in Barrett's esophagus19.
Since both sarcopenia and GERD are interlinked with metabolic syndrome, we developed a hypothesis that 
sarcopenia is associated with GERD. However, the data demonstrating this relationship have been scarce.
The aim of our study was to investigate the predictive factors for GERD, including erosive reflux disease 
(ERD), with a focus on sarcopenia and sarcopenic obesity among patients who were performed a health check-up 
program. In addition, we evaluated the correlation between skeletal muscle index (SMI) as an estimator of sarco-
penia and body mass index (BMI) that estimates obesity in patients with sarcopenic obesity.
Method
Study design and population. A total of 9,194 patients who underwent an upper gastrointestinal endos-
copy at the Health Promotion Center of the Gangnam Severance Hospital, Seoul, South Korea as part of a routine 
health check-up were considered for this cross-sectional and retrospective study. We reviewed the patients’ elec-
tronic medical records from August 2017 to August 2018, when is able to measure SMI in our check-up center. 
The exclusion criteria were as follows: (1) a personal history of malignancy including gastric cancer (n = 869), 
(2) a personal history of stomach operation, such as a resection of the stomach or gastrectomy (n = 65), and (3) 
incomplete electronic medical records (n = 42). As a result, 8,218 patients were enrolled in our study. All enrolled 
patients were Korean. Figure 1 shows a flow chart of the enrolled patients.
The study protocol conformed to the ethical guidelines of the World Medical Association Declaration of 
Helsinki and was approved by the Institutional Review Board of Gangnam Severance Hospital (IRB No: 3-2018-
0102). Since this study was a retrospective analysis of existing administrative and clinical data, informed consent 
was not required.
Anthropometric measurements. We measured anthropometric parameters in all enrolled patients. 
Body weight and height were measured to the nearest 0.1 kg and 0.1 cm, respectively with the patients barefoot 
and putting on light-weight clothing. Multi-frequency bioelectrical impedance analysis (ACCUNIQ BC 720; 
SELVAS healthcare, Korea) was used to measure skeletal muscle mass, which is considered an appropriate device 
to dual-energy X-ray absorptiometry20. ASM was calculated as the total of appendicular lean mass of both arms 
and legs21. BMI was defined as body weight (kg) divided by height squared (m2).
We adopted the definition of sarcopenia developed by Janssen et al.2; they used the SMI to evaluate the preva-
lence of sarcopenia and defined sarcopenia as a SMI less than one standard deviation below the sex-specific mean 
for healthy subjects aged 20 to 39 years. SMI was calculated by ASM as a percentage of body weight. In our study, 
the mean SMI of healthy adults was 32.9 ± 3.6% and 29.8 ± 3.1% in males and females, respectively. In our study, 
cutoff value for sarcopenia was 29.3% in males and 26.7% in females. Therefore, sarcopenia was diagnosed as 
SMI ≤ 29.3% in males and ≤ 26.7% in females. We used the definition of obesity with Asia-Pacific criteria22, which 
is a BMI ≥ 25 kg/m2. Sarcopenic obesity is the combination of sarcopenia and obesity in our study.
Questionnaire. All patients who underwent our health check-up program were asked to fill out a question-
naire. Smoking history, alcohol history, combined diabetes mellitus (DM), and diet, which included rapid intake, 
irregular intake, sweets, fatty foods, caffeinated drinks, and spicy foods, were included in the questionnaire. Rapid 
intake meant that it took less than 15 minutes to have one meal. Patients were asked to select “yes” or “no” for 
Figure 1. Flow chart of the enrolled patients.
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irregular intake. For the diet, which included sweets, fatty foods, caffeinated drinks, and spicy foods, a patient 
selected “yes” if they consumed that particular diet item over six times within seven days.
Upper gastrointestinal endoscopy. All enrolled patients were performed upper gastrointestinal endo-
scopic examination using an endoscope (GIF-H260; Olympus Medical Systems, Tokyo, Japan) with an electronic 
endoscopic system (EVIS LUCERA; Olympus Medical Systems). The diagnosis of GERD was made by endosco-
pists who had at least 3 years of experience. The severity of reflux esophagitis was graded according to the Los 
Angeles (LA) classification23. The GERD group was comprised of patients who had non-erosive reflux disease 
and ERD. Patients who had minimal change esophagitis were classified as non-erosive reflux disease, and patients 
with obvious evidence of esophageal mucosal injury on the endoscopy, such as Barrett's esophagus and LA grade 
A to D reflux esophagitis, were classified as ERD-(1) group. And LA grade B to D reflux esophagitis was classified 
as ERD-(2) group24.
Statistical analysis. Continuous variable values were reported as the mean ± standard deviation. The t-test 
or Wilcoxon rank-sum test was performed to compare continuous variables between the groups. Categorical 
variable values were reported as the number and percentage, and we used the chi-square test or Fisher’s exact test 
to compare categorical variables.
The Pearson's correlation analysis was used to evaluate the correlation between two continuous variables. 
Moreover, multivariate Cox regression analysis was performed to investigate the predictive factors for GERD and 
ERD. Since sarcopenic obesity is a combination of sarcopenia and obesity, two multivariate analyses were per-
formed. We used SPSS version 23.0 (IBM Corp., Armonk, NY, USA) for statistical analysis. Statistical significance 
was determined by a two-tailed P-value < 0.05.
Results
Baseline characteristics. Baseline characteristics of the study population are showed in Table 1. Of the 
8,218 patients, 4,622 (56.2%) were men, and the mean age was 48.9 ± 11.6 years. The average BMI was 23.9 ± 3.4 
kg/m2. The mean SMI was 32.2 ± 2.7% in male and 28.8 ± 3.0% in female. A total of 15.1% and 13.4% of the 
patients were diagnosed with sarcopenia and sarcopenic obesity, respectively. The male had a higher prevalence 
of sarcopenia (18.7% male vs 10.5% female) and sarcopenic obesity (17.2% male vs 8.5% female) than female.
A total of 3,414 patients were classified as GERD by endoscopic findings. Among these patients, 3,342 had 
reflux esophagitis, 1,991 had minimal change esophagitis, 1,148 had LA grade A, 191 had LA grade B, and 12 had 
LA grade C. Moreover, 72 had short-segment Barrett's esophagus.
Predictive factors for GERD. As a result of the univariate analysis, advanced age, male sex, obesity, 
smoking, alcohol, sarcopenia, sarcopenic obesity, and diet, which included sweets, fatty foods, and caffeinated 
drinks, had a significant association with an increased risk of GERD. In the multivariate analysis, sarcopenia was 
independent predictive factor for GERD (odds ratio [OR] = 1.170, 95% confidence interval [CI]: 1.016–1.346, 
P = 0.029). Moreover, male sex (OR = 1.493, 95% CI: 1.344–1.658, P < 0.001), smoking (OR = 1.139, 95% CI: 
1.007–1.287, P = 0.038), alcohol (OR = 1.121, 95% CI: 1.013–1.241, P = 0.027), and diet, which included sweets 
(OR = 1.132, 95% CI: 1.024–1.251, P = 0.015) and fatty foods (OR = 1.212, 95% CI: 1.085–1.354, P = 0.001), were 
independent predictive factors for GERD. However, obesity was not independently associated with GERD in 
multivariate analysis.
Predictive factors for ERD. Predictive factors for ERD-(1) group were shown in Tables 2 and 3. As a result 
of the univariate analysis, advanced age, male sex, obesity, smoking, alcohol, sarcopenia, sarcopenic obesity, 
and diet, which included fatty foods, caffeinated drinks, and spicy foods, had a significant association with an 
increased risk of ERD-(1) group (Table 2). Among these factors, sarcopenia (OR = 1.215, 95% CI: 1.019–1.449, 
P = 0.030), obesity (OR = 1.343, 95% CI: 1.163–1.552, P < 0.001), and sarcopenic obesity (OR = 1.406, 95% CI: 
1.195–1.654, P = 0.001) were independent predictive factors for ERD-(1). Moreover, male sex (OR = 2.447, 95% 
CI: 2.098–2.853, P < 0.001), smoking (OR = 1.259, 95% CI: 1.081–1.466, P = 0.003), and fatty foods (OR = 1.327, 
95% CI: 1.148–1.536, P < 0.001) had an independent association with ERD-(1) (Table 3).
Tables 4 and 5 show the predictive factors for ERD-(2) group. As a result of the univariate analysis, male sex, 
obesity, smoking, alcohol, DM, sarcopenia, sarcopenic obesity, and diet, which included fatty foods and caffein-
ated drinks had a significant association with an increased risk of ERD-(2) group (Table 4). As a result of the mul-
tivariate analysis, male (OR = 2.514, 95% CI: 1.756–3.598, P < 0.001), smoking (OR = 1.224, 95% CI: 1.042–1.464, 
P = 0.015), sarcopenia (OR = 1.375, 95% CI: 1.020–1.754, P = 0.040), obesity (OR = 2.564, 95% CI: 1.972–3.322, 
P < 0.001), and sarcopenic obesity (OR = 2.020, 95% CI: 1.515–2.703, P < 0.001) were independently associated 
with ERD-(2) group (Table 5).
Correlation between SMI and BMI in ERD patients. Since sarcopenia, obesity, and sarcopenic obesity 
were independent predictive factors for ERD, we performed an additional analysis to identify the correlation 
between SMI and BMI. Figure 2A shows the significantly negative correlation between SMI and BMI in the 
patients who were diagnosed with sarcopenic obesity in the ERD group. (Pearson’s correlation coefficient: −0.301, 
P < 0.001). According to sex, the male group (Pearson’s correlation coefficient: −0.682, P < 0.001, Fig. 2B) had 
a more strongly negative correlation than the female group (Pearson’s correlation coefficient: −0.587, P < 0.001, 
Fig. 2C).
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Univariate analysis
Control (n = 4,804) ERD-(1) (n = 1,423) P-value
Age (years, mean ± SD) 48.1 ± 11.7 49.5 ± 11.5 0.031
Male (n, %) 2,464 (51.3) 1,088 (76.5) <0.001
Obesity (n, %) 1,542 (32.1) 683 (48.0) <0.001
Current smoker (n, %) 755 (15.7) 387 (27.2) <0.001
Alcohol history (n, %) 3,081 (64.1) 1,055 (74.1) <0.001
Combined DM (n, %) 696 (14.5) 212 (14.9) 0.700
Diet style (n, %)
          Rapid intake 1,754 (36.5) 541 (38.0) 0.301
          Irregular intake 397 (27.9) 1,443 (30.0) 0.120
          Sweets 382 (26.8) 1,324 (27.6) 0.595
          Fatty foods 925 (19.3) 394 (27.7) <0.001
          Caffeinated drinks 2,230 (46.4) 756 (53.1) <0.001
          Spicy foods 655 (13.6) 237 (16.7) 0.004
Sarcopenia (n, %) 668 (13.9) 302 (21.2) <0.001
Sarcopenic obesity (n, %) 595 (12.4) 274 (19.3) <0.001
Table 2. Univariate analysis of the predictive facfstors for ERD-(1) group. ERD, erosive reflux disease; BMI, 
body mass index; DM, diabetes mellitus. ERD-(1) group: consisted of Barrett’s esophagus and LA grade A to D 
reflux esophagitis.
Characteristics All patients (N = 8,218)
Age (years, mean ± SD) 48.9 ± 11.6
Male (n, %) 4,622 (56.2)
Height (cm, mean ± SD) 166.6 ± 8.5
Weight (kg, mean ± SD) 66.6 ± 12.9
BMI (kg/m2, mean ± SD) 23.9 ± 3.4
Obesity (n, %) 2,799 (34.1)
SMI (%, mean ± SD)
          Male 32.2 ± 2.7
          Female 28.8 ± 3.0
Current smoker (n, %) 1,470 (17.9)
Alcohol history (n, %) 5,482 (66.7)
Combined DM (n, %) 1,190 (14.5)
Sarcopenia (n, %) 1,242 (15.1)
          Male 864/4,622 (18.7)
          Female 378/3,596 (10.5)
Sarcopenic obesity (n, %) 1103 (13.4)
          Male 797/4,622 (17.2)
          Female 306/3,596 (8.5)
Diet style (n, %)
          Rapid intake 2,938 (35.8)
          Irregular intake 2,406 (29.3)
          Sweets 2,343 (28.5)
          Fatty foods 1,759 (21.4)
          Caffeinated drinks 3,894 (47.4)
          Spicy foods 1,139 (13.9)
Endoscopic finding
          Barrett’s esophagus 72
          Minimal change esophagitis 1,991
          Reflux esophagitis LA grade A/B/C/D 1,148/191/12/0
Table 1. Baseline characteristics of the study population. BMI, body mass index; SMI, skeletal muscle index; 
DM, diabetes mellitus; GERD, gastroesophageal reflux disease.
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Discussion
Sarcopenia is a growing health concern because of its negative outcomes from functional decline to death, as well 
as the increasing worldwide prevalence25. There are several known risk factors for GERD, including obesity, struc-
tural abnormalities such as hiatal hernia, and specific diets and medications26. However, there have beeTablen no 
studies that link GERD and sarcopenia. Recent studies have reported that sarcopenic obesity has an influence 
on cardiometabolic diseases27–31. In these studies, sarcopenic obesity is a strongly associated with metabolic syn-
drome and has a higher impact on metabolic diseases and mortality than obesity or sarcopenia alone. To the best 
of our knowledge, this study is the first to identify an association between GERD and sarcopenia. Notably, the 
strength of our study is that we performed additional analysis between ERD and the “new concept” of sarcopenic 
obesity.
In the conclusion of our study, sarcopenia is associated with GERD. This association can be explained by 
metabolic syndrome. Previous study reported that volume of skeletal muscle fiber is related to the expression of 
glucose transporter type 4 (GLUT4), which enables the uptake of glucose32. Therefore, sarcopenia can induce an 
insulin intolerance that is a component of metabolic syndrome. There was a vicious cycle between sarcopenia 
and metabolic syndrome33. Muscle mass attenuation from sarcopenia induces lower physical activity that causes 
visceral f at to increase in the body. Since skeletal muscle is an insulin-response target tissue, patients with sarco-
penia develop progressive metabolic syndrome. Although precise mechanisms of association between sarcopenia 
and GERD are unclear, we guess that sarcopenia might be affect to mechanical barrier, such as function of esoph-
agus and stomach, thereby induce GERD. Moreover, cytokine signaling can be one of mechanisms as mentioned 
Multivariate analysis 1 Multivariate analysis 2
OR (95% CI) P-value OR (95% CI) P-value
Male 2.447 (2.098–2.853) <0.001 2.629 (2.264–3.052) <0.001
Current smoker 1.259 (1.081–1.466) 0.003 1.265 (1.087–1.473) 0.002
Alcohol history 1.093 (0.945–1.263) 0.230 1.082 (0.936–1.250) 0.286
Diet style
          Fatty foods 1.327 (1.148–1.536) <0.001 1.339 (1.158–1.548) <0.001
          Caffeinated drinks 1.040 (0.916–1.180) 0.546 1.051 (0.927–1.193) 0.438
          Spicy foods 0.981 (0.824–1.168) 0.829 0.994 (0.835–1.182) 0.944
Sarcopenia 1.215 (1.019–1.449) 0.030 — —
Obesity 1.343 (1.163–1.552) <0.001 — —
Sarcopenic obesity — — 1.406 (1.195–1.654) <0.001
Table 3. Multivariate analysis of the predictive factors for ERD-(1) group. OR, Odds ratio. ERD-(1) group: 
consisted of Barrett’s esophagus and LA grade A to D reflux esophagitis. Multivariate analysis 1: Adjusted for 
male, smoking, alcohol, diet style, sarcopenia, and obesity. Multivariate analysis 2: Adjusted for male, smoking, 
alcohol, diet style, and sarcopenic obesity.
Univariate analysis
Control 
(n = 4,804)
ERD-(2) 
(n = 275) P-value
Age (years, mean ± SD) 49.5 ± 11.5 49.0 ± 11.8 0.486
Male (n, %) 2,464 (51.3) 223 (81.1) <0.001
BMI (kg/m2, mean ± SD) 0) 23.7 ± 3.3 26.0 ± 2.9 <0.001
Obesity (n, %) 1,542 (32.1) 171 (62.2) <0.001
Current smoker (n, %) 755 (15.7) 85 (30.9) <0.001
Alcohol history (n, %) 3,081 (64.1) 208 (75.6) <0.001
Combined DM (n, %) 696 (14.5) 53 (19.3) 0.030
Diet style (n, %)
          Rapid intake 1,754 (36.5) 104 (37.8) 0.662
          Irregular intake 397 (27.9) 86 (31.3) 0.371
          Sweets 382 (26.8) 76 (27.6) 0.732
          Fatty foods 925 (19.3) 71 (25.8) 0.008
          Caffeinated drinks 2,230 (46.4) 147 (53.5) 0.023
          Spicy foods 655 (13.6) 35 (12.7) 0.669
Sarcopenia (n, %) 668 (13.9) 75 (27.3) <0.001
Sarcopenic obesity (n, %) 595 (12.4) 70 (25.5) <0.001
Table 4. Univariate analysis of the predictive factors for ERD-(2) group. ERD, erosive reflux disease; BMI, body 
mass index; DM, diabetes mellitus. ERD-(2) group: consisted of Barrett’s esophagus and LA grade B to D reflux 
esophagitis.
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in the section of introduction. Previous study reported that cytokine such as TNF-α, TWEAK, and IL-6 were 
related to skeletal muscle wasting34.
The prevalence of GERD in the Asian population has been reported as generally less than 10%35. However, 
the prevalence of GERD in our study was much higher at 41.5%. In addition, obesity, which is a known potential 
risk factor for GERD, did not have a statistical significance in our multivariate analysis36. These results were due 
to the following: First, since the questionnaire of our check-up center did not have symptoms for GERD, such as 
heartburn and regurgitation, non-erosive reflux disease was diagnosed by only endoscopic findings of minimal 
change esophagitis, which is ambiguous; second, the characteristics of the non-erosive reflux disease group was 
heterogeneous, and they may have had functional dyspepsia or psychological comorbidities.
Multivariate analysis 1 Multivariate analysis 2
OR (95% CI) P-value OR (95% CI) P-value
Male 2.514 (1.756–3.598) <0.001 3.085 (2.174–4.379) <0.001
Current smoker 1.224 (1.042–1.464) 0.015 1.256 (1.062–1.488) 0.008
Alcohol history 1.104 (0.812–1.499) 0.528 1.086 (0.800–1.473) 0.599
DM 1.221 (0.889–1.678) 0.217 1.259 (0.918–1.727) 0.152
Diet style
         Fatty foods 1.135 (0.850–1.517) 0.391 1.175 (0.880–1.567) 0.274
          Caffeinated drinks 1.002 (0.773–1.287) 0.987 1.025 (0.795–1.319) 0.853
Sarcopenia 1.375 (1.020–1.754) 0.040 — —
Obesity 2.564 (1.972–3.322) <0.001 — —
Sarcopenic obesity — — 2.020 (1.515–2.703) <0.001
Table 5. Multivariate analysis of the predictive factors for ERD-(2) group. OR, Odds ratio; DM, diabetes 
mellitus. ERD-(2) group: consisted of Barrett’s esophagus and LA grade B to D reflux esophagitis. Multivariate 
analysis 1: Adjusted for male, smoking, alcohol, DM, diet style, sarcopenia, and obesity. Multivariate analysis 2: 
Adjusted for male, smoking, alcohol, DM, diet style, and sarcopenic obesity.
Figure 2. Correlation analysis between body mass index (BMI) and skeletal muscle index (SMI) in patients 
diagnosed with sarcopenic obesity in the ERD group. (A) In both the male and female groups (B) In the male 
group (C) In the female group.
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Thus, we performed an additional analysis on 1,423 (17.3%) patients who had ERD-(1), which has a more 
definitive mucosal injury and is more specific for GERD. Sarcopenia, obesity, and sarcopenic obesity were inde-
pendent predictive factors for ERD-(1) group. Interestingly, sarcopenic obesity (OR 1.406) was more predictive 
than sarcopenia (OR 1.215) or obesity (OR 1,343) for ERD-(1) group. This result suggests that sarcopenia and 
obesity may have a synergistic influence on ERD-(1) group. Moreover, there was a significantly negative correla-
tion between SMI and BMI, especially in the male patients. LA grade B to D reflux esophagitis (ERD-(2) group, 
n = 203) are more specific endoscopic findings for GERD. In this analysis, sarcopenia (OR 1.493), obesity (OR 
1.229), and sarcopenic obesity (OR 1.616) also associated with ERD-(2) group. This result overcame our study’s 
limitation and support conclusion of our study.
As we mentioned above, the prevalence of sarcopenia is different according to race. In the result of meta- anal-
ysis, the prevalence of sarcopenia was different according to the method to measure muscle mass9. When method 
BIA used, non-Asian (19%) was higher than Asian (10%) in male, and non-Asian (20%) was higher than Asian 
(11%) in female. When method DXA used, Asian (9%) was higher than non-Asian (6%) in male, and non-Asian 
(10%) was higher than Asian in female (6%). Therefore, it is necessary to make consensus diagnostic tool for 
sarcopenia, and further study is warranted.
There were several limitations to our study. First, GERD was diagnosed by endoscopic finding with mucosal 
injury. We retrospectively reviewed the result section for upper endoscopy of our electronic medical records. 
Moreover, we also diagnosed Barrett’s esophagus by endoscopic finding, not histologic confirmation. Second, 
since our study design was cross-sectional for the check-up cohort, there was a selection bias that included the 
individual’s food habits and socioeconomic status. Third, our cross-sectional study design made it hard to empha-
size the temporal relationship between sarcopenia and the development of GERD. Fourth, despite current consen-
sus definitions such as the European Working Group on Sarcopenia in Older People (EWGSOP), the European 
Society for Clinical Nutrition and Metabolism Special Interest Groups (ESPEN-SIG), and the International 
Working Group on Sarcopenia (IWGS) adopted muscle mass and function to define sarcopenia3,37–39, our study 
used only muscle mass. This was because our check-up center did not have an equipment to evaluate muscle func-
tion. In addition, routine program of most check-up centers only includes evaluation for muscle mass. Therefore, 
the data of our study may be enough worth predicting GERD in healthy subjects. Fifth, the patients’ information, 
such as combined DM, alcohol, smoking, and diet, were collected from a questionnaire. However, it is difficult to 
evaluate an exact amount of alcohol, frequency for smoking, and amount and concentration of food components. 
Moreover, taking acid suppressive drugs, such as proton pump inhibitor, is a confounding factor affecting GERD. 
However, questionnaire of our check-up center did not include history of medication for acid suppressive drug. 
Finally, because of the retrospective aspect of our study, we may have collected some incomplete data.
In conclusion, sarcopenia is associated with GERD. Moreover, sarcopenia and sarcopenic obesity are predic-
tive factors for ERD. Our check-up center measured the patients’ anthropometric profile, which included body 
weight, height, and skeletal muscle mass. Therefore, our study is meaningful because the patients’ anthropometric 
measurements proved to be a useful data to predict GERD and ERD. Since the clinical presentations of sarcopenia 
are not specific, early detection by a routine health check-up is important. This study identified the association 
between sarcopenia and GERD, and proved our hypothesis. Further studies should be warranted to evaluate the 
mechanism for this relationship.
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